Intralesional Insulin Is Superior to Intralesional Botulinum Toxin-A in the Treatment of Keloids

Both insulin and BTX-A show a promising role in managing keloids, with insulin demonstrating better efficacy. Botulinum toxin A is better recommended as an adjuvant therapy alongside other mainstay treatment modalities. Larger-scale studies are needed to confirm their roles and establish guidelines for their use.